| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2013 | WO2012010663A9 2,3,5-trisubstituted thiophene compounds and uses thereof |
| 01/24/2013 | WO2011159491A8 Controlled release levetiracetam formulations |
| 01/24/2013 | US20130024961 Methods of Modulating Thrombocytopenia and Modified Transgenic Pigs |
| 01/24/2013 | US20130024960 Optimised coding sequence and promoter |
| 01/24/2013 | US20130024956 Antibodies to cd40 |
| 01/24/2013 | US20130024953 Methods of Treating Disorders Associated with Protein Aggregation |
| 01/24/2013 | US20130023879 Method for augmenting, reducing, and repairing bone with thermoplastic materials (as amended) |
| 01/24/2013 | US20130023736 Systems for drug delivery and monitoring |
| 01/24/2013 | US20130023714 Medical and Imaging Nanoclusters |
| 01/24/2013 | US20130023688 Phosphorus-containing compounds with polymeric chains, and methods of making and using the same |
| 01/24/2013 | US20130023663 Substituted stilbenes and their reactions |
| 01/24/2013 | US20130023590 Aqueous compositions comprising resveratrol and methods for making them |
| 01/24/2013 | US20130023589 Medication for therapy or prophylaxis of asthma |
| 01/24/2013 | US20130023588 Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| 01/24/2013 | US20130023587 Compositions and methods for the treatment of cancer |
| 01/24/2013 | US20130023586 Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
| 01/24/2013 | US20130023585 Neuraminidase Inhibitors |
| 01/24/2013 | US20130023584 Theaflavin Compositions, Related Processes and Methods of Use |
| 01/24/2013 | US20130023583 Theaflavin Compositions, Related Processes and Methods of Use |
| 01/24/2013 | US20130023580 Compositions and Methods for Inhibiting Expression of XBP-1 Gene |
| 01/24/2013 | US20130023579 Modulation of angiopoietin-like 3 expression |
| 01/24/2013 | US20130023578 siRNA for inhibition of c-Met expression and anticancer composition containing the same |
| 01/24/2013 | US20130023577 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
| 01/24/2013 | US20130023576 Pyrazole Compounds as CRTH2 Antagonists |
| 01/24/2013 | US20130023575 Compositions and methods for the treatment of ocular surface allergies |
| 01/24/2013 | US20130023574 Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same |
| 01/24/2013 | US20130023573 Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| 01/24/2013 | US20130023572 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| 01/24/2013 | US20130023570 Polymorphs of darunavir |
| 01/24/2013 | US20130023569 Use of Deferiprone for Treatment and Prevention of Iron-Related Eye Disorders |
| 01/24/2013 | US20130023568 Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses |
| 01/24/2013 | US20130023567 Novel Compounds |
| 01/24/2013 | US20130023566 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives |
| 01/24/2013 | US20130023565 Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use |
| 01/24/2013 | US20130023564 Piperidinyl derivative as a modulator of chemokine receptor activity |
| 01/24/2013 | US20130023563 Amidinoaniline derivative |
| 01/24/2013 | US20130023562 Novel piperidine derivatives |
| 01/24/2013 | US20130023561 Facially Amphiphilic Polymers and Oligomers and Uses Thereof |
| 01/24/2013 | US20130023560 Methods and compositions for the treatment of iron toxicity |
| 01/24/2013 | US20130023559 Alcohol free formulation of argatroban |
| 01/24/2013 | US20130023558 CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-c]PYRIDINE RING |
| 01/24/2013 | US20130023557 Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| 01/24/2013 | US20130023556 Autotaxin inhibitors |
| 01/24/2013 | US20130023555 Kinase inhibitor with improved solubility profile |
| 01/24/2013 | US20130023554 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof |
| 01/24/2013 | US20130023553 Pegylated opioids with low potential for abuse and side effects |
| 01/24/2013 | US20130023552 Small molecules with antimalarial activity |
| 01/24/2013 | US20130023551 Dispiro tetraoxane compounds |
| 01/24/2013 | US20130023550 Pharmaceutical compositions and methods of making same |
| 01/24/2013 | US20130023549 Pharmaceutical Compositions Comprising Nilotinib or Its Salt |
| 01/24/2013 | US20130023548 Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 01/24/2013 | US20130023547 Dispersible tablet |
| 01/24/2013 | US20130023546 Thienopyrimidine derivatives |
| 01/24/2013 | US20130023545 Cycloalkyloxycarboxylic acid derivatives |
| 01/24/2013 | US20130023544 CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING |
| 01/24/2013 | US20130023543 Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/24/2013 | US20130023542 Human protein tyrosine phosphatase inhibitors and methods of use |
| 01/24/2013 | US20130023541 Voltage-gated sodium channel blockers |
| 01/24/2013 | US20130023540 Treatment of mastitis |
| 01/24/2013 | US20130023539 Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43) |
| 01/24/2013 | US20130023538 Heteroaryl Derivatives as CFTR Modulators |
| 01/24/2013 | US20130023537 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 01/24/2013 | US20130023536 Fixed dose combination of bimatoprost and brimonidine |
| 01/24/2013 | US20130023535 Method of preventing and/or treating diabetic neuropathy |
| 01/24/2013 | US20130023534 Pyrazolyl-pyrimidines as kinase inhibitors |
| 01/24/2013 | US20130023533 New 5-alkynyl-pyridines |
| 01/24/2013 | US20130023532 Indazolyl-pyrimidines as kinase inhibitors |
| 01/24/2013 | US20130023531 Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| 01/24/2013 | US20130023530 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| 01/24/2013 | US20130023529 Methods Involving Aldose Reductase Inhibitors |
| 01/24/2013 | US20130023528 Prolylhydroxylase inhibitors and methods of use |
| 01/24/2013 | US20130023527 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| 01/24/2013 | US20130023526 Isoxazolines as Therapeutic Agents |
| 01/24/2013 | US20130023525 Gyrase inhibitors and uses thereof |
| 01/24/2013 | US20130023524 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it |
| 01/24/2013 | US20130023523 Pyridazino[4,5-d]pyrimidin-5(6h)-one inhibitors of kinases |
| 01/24/2013 | US20130023522 Benzamides |
| 01/24/2013 | US20130023521 Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
| 01/24/2013 | US20130023520 Anaesthetic eye solution and method of use |
| 01/24/2013 | US20130023519 5-alkynyl-pyridines |
| 01/24/2013 | US20130023518 Novel 3,3-dimethyl tetrahydroquinoline derivatives |
| 01/24/2013 | US20130023517 Therapeutic methods employing substituted piperidines which are CCR3 antagonists |
| 01/24/2013 | US20130023516 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics |
| 01/24/2013 | US20130023515 Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| 01/24/2013 | US20130023514 Substituted pyrrolotriazines as protein kinase inhibitors |
| 01/24/2013 | US20130023513 Methods and Compositions for Treating Cardiovascular Disorders |
| 01/24/2013 | US20130023512 Compositions for Combating Beta-Lactamase-Medicated Antibiotic Resistance Using Beta-Lactamase Inhibitors Useful For Injection |
| 01/24/2013 | US20130023511 Organometallic complexes as therapeutic agents |
| 01/24/2013 | US20130023510 Arachidonic acid analogs and methods for analgesic treatment using same |
| 01/24/2013 | US20130023509 Hyaluronic acid based copolymers |
| 01/24/2013 | US20130023508 Hyaluronic acid based copolymers |
| 01/24/2013 | US20130023507 Hyaluronic acid based copolymers |
| 01/24/2013 | US20130023506 Method for treating uterine fibroids |
| 01/24/2013 | US20130023505 Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
| 01/24/2013 | US20130023504 Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways |
| 01/24/2013 | US20130023503 Nk1 antagonists |
| 01/24/2013 | US20130023502 Substituted pyridinyl-pyrimidines and their use as medicaments |
| 01/24/2013 | US20130023501 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue |
| 01/24/2013 | US20130023500 Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof |
| 01/24/2013 | US20130023499 Certain substituted amides, method of making, and method of use thereof |